Examining blood clotting in autoimmune skin diseases
Coagulopathy of Immunodermatologic Diseases The Molecular, Prognostic, and Therapeutic Implications of Crosstalk Between Coagulation, Fibrinolysis, and Inflammation in Immune-Mediated Skin Diseases
University of Nebraska · NCT06037187
This study looks at blood clotting in people with autoimmune skin diseases to see how it differs from those without these conditions.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 39 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | University of Nebraska (other) |
| Locations | 1 site (Omaha, Nebraska) |
| Trial ID | NCT06037187 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the coagulation and fibrinolysis profiles in patients with autoimmune skin diseases. Blood samples will be collected from individuals with both active and well-controlled immune-mediated skin conditions, as well as from a control group of dermatology outpatients without such diseases. The study will compare coagulation and inflammatory markers between these groups to better understand the implications of coagulation profiles in autoimmune skin diseases. The findings may pave the way for future research on the clinical relevance of these profiles.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with immune-mediated skin diseases such as bullous pemphigoid or pemphigus vulgaris.
Not a fit: Patients with other autoimmune diseases not in remission or those with a history of internal malignancy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of coagulation issues in patients with autoimmune skin diseases, potentially leading to improved management strategies.
How similar studies have performed: While this approach is relatively novel, previous studies have explored related areas, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. For the study group: diagnosis of immune-mediated skin disease including but not limited to bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, cutaneous lupus erythematosus, dermatomyositis 2. For control group: no diagnosis of immune-mediated skin 3. For study group: receiving care from one or more of the Principal or Secondary Investigators Exclusion Criteria: 1. Unfit to provide consent 2. P2Y12 inhibitor use in the past 4 weeks 3. History of internal malignancy prior to enrolling in the study or suspected internal/systemic malignancy during time of the study (i.e. will not exclude pre-malignant or local, early stage cutaneous malignancies) 4. Major surgery within 4 weeks of the study or trauma (e.g., accident-causing bone fracture) within 4 weeks of the study 5. Other autoimmune diseases not in remission defined as flare in the last 12 weeks 6. If patient is unable to provide detailed history and if we do not have sufficient history on record. 7. Less than 19 years of age
Where this trial is running
Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska, United States (RECRUITING)
Study contacts
- Principal investigator: Erin X Barrett, MD — University of Nebraska
- Study coordinator: Megan E Wackel, MS
- Email: megan.wackel@unmc.edu
- Phone: 402-559-3825
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Autoimmune Bullous Dermatosis